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Rewarming from hypothermia is often challenged by coexisting cardiac dysfunction,
depressed organ blood flow (OBF), and increased systemic vascular resistance. Previous
research shows cardiovascular inotropic support and vasodilation during rewarming
to elevate cardiac output (CO). The present study aims to compare the effects of
inodilatation by levosimendan (LS) and vasodilation by nitroprusside (SNP) on OBF
and global oxygen transport during rewarming from hypothermia. We used an in vivo
experimental rat model of 4 h 15◦C hypothermia and rewarming. A stable isotope-labeled
microsphere technique was used to determine OBF. Cardiac and arterial pressures were
monitored with fluid-filled pressure catheters, and CO was measured by thermodilution.
Two groups were treated with either LS (n = 7) or SNP (n = 7) during the last hour
of hypothermia and throughout rewarming. Two groups served as hypothermic (n = 7)
and normothermic (n = 6) controls. All hypothermia groups had significantly reduced
CO, oxygen delivery, and OBF after rewarming compared to their baseline values. After
rewarming, LS had elevated CO significantly more than SNP (66.57 ± 5.6/+30% vs.
54.48 ± 5.2/+14%) compared to the control group (47.22 ± 3.9), but their ability
to cause elevation of brain blood flow (BBF) was the same (0.554 ± 0.180/+81 vs.
0.535 ± 0.208/+75%) compared to the control group (0.305 ± 0.101). We interpret the
vasodilator properties of LS and SNP to be the primary source to increase organ blood
flow, superior to the increase in CO.
Keywords: hypothermia, nitroprusside, levosimendan, rewarming shock, targeted therapeutic strategies,
microcirculation
INTRODUCTION
Clinical presentation of accidental hypothermia and rewarming is associated with hypotension,
hypoperfusion, and vital organ injury (1, 2). Coined rewarming shock, this unstable hemodynamic
state (3–5) contributes to the lethality of 28–35% in accidental hypothermia patients (6, 7). The
underlying mechanisms of rewarming shock are yet not fully understood. Clinical experience
and experimental studies have identified hypothermia-induced cardiac dysfunction and elevated
systemic vascular resistance (SVR) as fundamental mechanisms (5, 8). Hypothermia-induced
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cardiac dysfunction has been linked to inotropic failure
and dysregulation of myocardial beta-receptors. The current
European guidelines for resuscitation during hypothermia
focus on mechanical circulatory support in unstable patients
and restrictive adrenergic intervention, significantly below
30◦C (9). Thus, experimental studies are needed to improve
our understanding of rewarming shock and identify possible
pharmacological treatment options.
A combination of positive inotropy and vasodilation, i.e.,
inodilation, with levosimendan (LS), or vasodilation only
with sodium nitroprusside (SNP), have both demonstrated to
elevate cardiac output (CO) and reduce SVR in experimental
models of hypothermia and rewarming (8, 10, 11). The results
show LS and SNP to elevate CO by +166 and +77%,
respectively (8, 10). LS increases Ca2+ sensitivity of the cardiac
contractile apparatus and open ATP-dependent K+-channels
in smooth muscle, resulting in elevated cardiac inotropy and
vasodilation. LS also inhibits phosphodiesterase-3, elevating
cyclic adenosine monophosphate (cAMP), promoting additional
positive inotropy and vasodilation (12). SNP vasodilates by
activating smooth muscle cyclic guanosine monophosphate
(cGMP) (13), and in vivo studies show no changes in cardiac
contractility (14).
Organ blood flow (OBF) and oxygen transport (DO2) are
essential factors in the treatment of critical care patients (15).
The pharmacological elevation of OBF improves short-term
organ function and reduce mortality of patients in circulatory
shock (16, 17). While studies conducted during normothermic
conditions have shown elevated OBF by both LS and SNP (18–
20), little knowledge exists on their effects during rewarming
from hypothermia. It is therefore vital to assess if their
beneficial effects on global hemodynamic function translate into
improved OBF (8, 10). With this in mind, we hypothesize
that the combined inotropic and vasodilatory effects of LS
improve OBF more than isolated vasodilation by SNP after
rewarming from hypothermia. To test our hypothesis, we
used an in vivo rat model instrumented for measurements of
hemodynamic function and OBF during cooling, 3 h stable
hypothermia, and rewarming. Pharmacologic interventions were




The main aim of this study was to investigate if the beneficial
effects of LS and SNP on cardiac function translate into
improved organ perfusion during hypothermia and rewarming.
Four experimental groups were included: control (n =
7), Levosimendan (n = 7), Nitroprusside (n = 7), and
Normothermic control (n= 6).
Abbreviations: SVR, systemic vascular resistance; LS, levosimendan; SNP, sodium
nitroprusside; CO, cardiac output; OBF, organ blood flow; DO2, oxygen transport;
HR, heart rate; SV, stroke volume; CI, cardiac index; SaO2, oxygen saturation; Hb,
hemoglobin; CaO2, Arterial blood oxygen content; CvO2, venous blood oxygen
content; VO2, oxygen consumption;MAP,mean arterial pressure; BBF, brain blood
flow; MBF, myocardial blood flow; RBF, renal blood flow; SBF, stomach blood flow.
Control (n = 7)
The animals were cooled to and kept at 15◦C for 3 h. After 2 h,
the animals received a bolus dose of 0.33ml of 5% glucose over
10min, followed by a continuous infusion of 0.5 ml/h during
the last hour of hypothermia and until rewarming was completed
at 37◦C.
Levosimendan (n = 7)
The animals were cooled to and kept at 15◦C for 3 h. After
2 h, the animals received a bolus dose of 24 µg/kg/min
levosimendan over 10min, followed by a continuous 0.6
µg/kg/min infusion during the last hour of hypothermia and
throughout rewarming (10).
Nitroprusside (n = 7)
The animals were cooled to and kept at 15◦C for 3 h. After 2 h, an
infusion of nitroprusside was started at 0.625 µg/kg/min. During
rewarming, the dose was titrated to reduce mean arterial pressure
(MAP) by 30% compared to historical controls (8). On average,
each rat received 0.178mg of nitroprusside.
Normothermic Control (n = 6)
The animals were kept at 37◦C for 5 h. After 2.5 h, the
animals received a 10-min bolus infusion of 2.0 ml/h glucose
(5%), followed by a 0.5 ml/h infusion lasting throughout the
remaining experiment.
Hemodynamic Data
Arterial pressure was obtained with a fluid-filled 22G cannula
inserted in the left femoral artery and connected to a fluid
manometer. Left ventricular pressure was obtained with a fluid-
filled catheter inserted into the right carotid artery and advanced
to the left ventricle under pressure guidance and connected to
a manometer.
CO was measured with the thermodilution method, by
injecting 0.15ml of precooled (5◦C) 0.9% saline through the
jugular vein (21). The rapid change in temperature was recorded
by a thermocouple, inserted into the left femoral artery, and
advanced to the ascending aortic arch. Thermodilution curves
were recorded and analyzed in LabChart 8.0. In the hypothermia
groups, CO was measured at 37, 30, 22, and 15◦C during cooling
and rewarming. In the normothermia group, CO was measured
at baseline (37◦CBL) and, after that, hourly till final recording
(37◦C5h). Heart rate (HR) was calculated based on the femoral
pressure signal, and SVR, stroke volume (SV), and cardiac
index (CI) were calculated using the following formulas: SVR =
MAP/CO, SV= CO/HR, and CI= CO/9.83∗[body weight(2/3)].
To investigate organ blood flow, we applied the stable isotope
microsphere technique (22). A volume of 0.5ml, containing
250,000 microspheres/ml (BioPal Mi, USA), labeled with either
lutetium or samarium, was injected into the left ventricle using
the catheter. Simultaneously, a reference sample, 0.5 ml/min, was
drawn from the left femoral artery (2, 23, 24). After euthanasia,
the brain and cerebellum, heart, kidneys, liver, and stomach
were harvested, washed in SanSaline (BioPal), weighed, and
dried. Quantification ofmicrospheres in tissue and blood samples
was done by BioPal (Mi, USA). Later, OBF was calculated by
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normalizing organ microsphere concentration (disintegration
per minute/g) with the microsphere concentration of the
reference sample (disintegration per minute/ml/min) (22). In
the hypothermia groups, OBF was measured during rewarming
at 30 and 37◦C. In the normothermia group (37◦C), OBF was
measured at baseline.
Biochemical Data
Arterial blood was analyzed for pO2, pCO2, oxygen saturation
(SaO2), pH, hemoglobin (Hb), hematocrit, and lactate. HCO
−
3
and base excess were automatically calculated based on the
measured data (Rapidlab 800, Chiron Diagnostics). Blood gases
were analyzed at 37◦C and not corrected for core temperature
(25). In the hypothermia groups, arterial blood gas analyses
were obtained at baseline, during cooling at the start of stable
hypothermia (15◦C0), during rewarming at 30◦C (30◦CRW), and
after rewarming (37◦CRW). At 37◦CRW, a venous blood gas was
also sampled. In the normothermia group, arterial blood gases
were analyzed at 37◦CBL, and finally, after 5 h, also venous blood
gases were analyzed. Arterial and venous blood oxygen content
(CaO2 and CvO2), DO2, and oxygen consumption (VO2) were
calculated using the following formulas: CaO2 and CvO2 = (Hb
× 1.34× SaO2/100)+ (pO2 × 0.0031× 7.5), DO2 =CaO2 ×CO
and VO2 = CO× (CaO2 – CvO2).
Levosimendan and Nitroprusside
Levosimendan was purchased from Orion pharma as SIMDAX R©
(2.5 mg/ml). On the day of the experiment, it was diluted in 5%
glucose (10). Dilution was calculated in each experiment to adjust
for body weight.
Nitroprusside was purchased from Hospira as
NITROPRESS R© (25 mg/ml). On the day of the experiment, it
was diluted to 0.125 mg/ml (1:200) in 5% glucose (8).
Statistical Analyses
All statistical analysis were performed using SigmaPlot
13.0 (SAS).
The sample size was calculated with three independent
sample size analysis. The first two used the expected difference
between myocardial blood flow and mean arterial pressure after
rewarming in the three group thermic groups. The third used
the expected change in myocardial blood flow after rewarming
compared to baseline.
Based on these sample size analyses, we concluded that a total
of 27 animals were needed to attain a statistical power >0.8.
Hemodynamic results were analyzed with a two-way repeated
measure ANOVA analysis. Post hoc analysis and all group
comparisons were performed using a Holm–Sidak method.
Within-group comparisons of organ blood flow and blood
gas data were done using repeated measure one-way ANOVA.
Post hoc analyses were performed using a Holm–Sidak method.
Between-group analyses at baseline, during, and after rewarming
were done using a one-way ANOVA. Post hoc analyses were
performed using a Holm–Sidak method.
RESULTS
Organ Blood Flow
Figure 1 compared to 37◦CBL, blood flow in the brain, stomach,
right, and left kidney was reduced in all groups at 30◦CRW. No
difference in blood flow of other organs was found between the
three groups.
At 37◦CRW, the control and LS-treated groups demonstrated
significant reductions in blood flow to all organs, except for the
liver, compared to 37◦CBL Similar results were found in the SNP
group. However, heart blood flow was not reduced at 37◦CRW
At 37◦CRW, both LS and SNP elevated brain blood flow
compared to the control group. Blood flow in the heart was
elevated in the SNP-treated group compared to both the control
group and LS. Blood flow in the stomach was elevated in the SNP
group compared to the control group. No difference was found
between the three groups in kidneys or liver blood flow.
Hemodynamic Results
Table 1 and Figure 2 no differences were found in any of the
hemodynamic variables between the three hypothermia groups
at baseline (37◦CBL).
At 30◦C during rewarming (30◦CRW), all three groups,
independent of intervention, showed depressed MAP, CI, CO,
and HR when compared to 37◦CBL.
At 30◦CRW, CI, CO, and SV were significantly higher in the
LS group compared to the control. Further, SVR was reduced
in both SNP and LS groups compared to the control. No
differences were found between SNP and LS in any of the other
hemodynamic variables.
Compared to 37◦CB, SV was depressed in both the control
and the SNP group at 37◦C after rewarming (37◦CRW). SVR
was elevated only in the control group at 37◦CRW compared to
37◦CBL. At 37◦CRW, MAP, CI, and CO were all depressed in all
three groups, while SVwas depressed only in the SNP and control
groups compared to 37◦CBL.
At 37◦CRW, CO, CI, and SV were significantly higher and
SVR significantly lower in the LS-treated group compared to
the control. Compared to the control group, SNP significantly
elevated CO and CI and reduced MAP and SVR. CO, CI, and
MAP were significantly higher with LS than SNP.
Blood Gas Results
Table 2 no differences were found in arterial blood gases between
the three hypothermia groups at 37◦CBL.
Compared to 37◦CBL, Hb), hematocrit and lactate were
significantly elevated at 30◦CRW in all groups. SaO2 was elevated
in the control group, and pCO2 was elevated in the SNP group.
Further, DO2, pH, base excess, and HCO
−
3 were significantly
reduced in all groups at 30◦CRW. In addition, SaO2 was decreased
in the control group.
At 30◦CRW, DO2 was significantly higher in the LS group than
in the control. Further, plasma lactate levels were elevated in the
SNP group compared to both control and LS groups. No other
between-group differences were found at 30◦CRW.
At 37◦CRW Hb, hematocrit, pO2, and lactate were elevated in
all groups compared to 37◦CBL. Further, DO2, pH, base excess,
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FIGURE 1 | Organ blood flow at baseline (37◦CBL ), during and after rewarming (30 and 37
◦CRW) from hypothermia in untreated and treated rats with levosimendan or
nitroprusside (each group n = 7). Values are mean ± SD. *P < 0.05 vs. control group at corresponding temperatures,
†
P < 0.05 vs. levosimendan group at
corresponding temperatures, ¤P < 0.05 vs. 37◦CBL (Holm–Sidak method).
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TABLE 1 | Heart rate (HR), mean arterial pressure (MAP), stroke volume (SV), cardiac output (CO), cardiac index (CI), and systemic vascular resistance (SVR) at baseline
(37◦CBL ), during and after rewarming (30 and 37
◦CRW) from hypothermia in untreated and treated rats with levosimendan or nitroprusside (each group n = 7).




HR (beats/min) Control 433 ± 27 312 ± 23¤ 411 ± 39
Levosimendan 435 ± 34 296 ± 41¤ 428 ± 63
Nitroprusside 449 ± 24 284 ± 41¤ 417 ± 26
MAP (mmHg) Control 115.1 ± 8.8 94.2 ± 17.1¤ 80.8 ± 13.5¤
Levosimendan 118.4 ± 13.8 81.5 ± 12.5¤ 86.7 ± 10.3¤
Nitroprusside 115.3 ± 12.6 71.3 ± 5.2¤* 69.6 ± 12.7¤
†
SV (µL) Control 186 ± 19 129 ± 27¤ 116 ± 11¤
Levosimendan 192 ± 16 180 ± 33* 159 ± 31*
Nitroprusside 182 ± 13 167 ± 69¤ 131 ± 8¤
CO (mL/min) Control 80.41 ± 6.5 40.03 ± 8.1¤ 47.22 ± 3.9¤
Levosimendan 83.09 ± 5.8 52.24 ± 4.8¤* 66.57 ± 5.6¤*
Nitroprusside 81.47 ± 6.1 45.28 ± 10.7¤ 54.48 ± 5.2¤
†
CI (mL/min/g) Control 0.18 ± 0.02 0.09 ± 0.01¤ 0.10 ± 0.01¤
Levosimendan 0.19 ± 0.02 0.12 ± 0.01¤* 0.15 ± 0.01¤*
Nitroprusside 0.19 ± 0.01 0.10 ± 0.02¤ 0.12 ± 0.01¤*
†
SVR (mmHg/mL/min) Control 1.44 ± 0.17 2.37 ± 0.26¤ 1.71 ± 0.20 ¤
Levosimendan 1.43 ± 0.20 1.57 ± 0.26* 1.31 ± 0.18*
Nitroprusside 1.42 ± 0.14 1.64 ± 0.31* 1.27 ± 0.12*
Values are mean ± SD.
*P < 0.05 vs. control group at corresponding temperatures.
†
P < 0.05 vs. levosimendan group at corresponding temperatures.
¤P < 0.05 vs. 37◦CBL within-group (Holm–Sidak method).
and HCO−3 were significantly reduced in all groups at 37
◦CRW.
In addition, SaO2 was reduced in the control group.
At 37◦CRW, DO2, and VO2 were significantly elevated in the
LS-treated group than in the SNP and control. No differences
were found between groups in other variables at 37◦CRW.
DISCUSSION
The main findings of this study are that LS and SNP equally
improved blood flow to the brain, despite elevating cardiac
output to different levels. When comparing the effects of
two different pharmacologic interventions during rewarming,
vasodilation by SNP vs. inotropic support plus vasodilation
by LS, we find that, although LS is superior to SNP to
restore global hemodynamic function, OBF is equally or better
preserved after intervention with SNP. This finding indicates that
increased vascular resistance is a central element in the complex
pathophysiology of cardiac dysfunction and reduced OBF after
rewarming from hypothermia.
The aim of this experiment was to verify if the documented
effects that both LS and SNP to elevate OBF during
normothermic conditions (18–20) are valid also during
rewarming from hypothermia. As a surrogate for monitoring
organ microcirculatory variables, in clinical practice, we usually
pay attention to variables such as CO, HR, MAP, and SVR.
The specific aim was to test our hypotheses that the combined
inotropic and vasodilatory effects of LS would improve OBF over
that of the isolated vasodilation offered by SNP after rewarming
from hypothermia. However, this experiment indicates that,
during rewarming, peripheral vasodilation is superior to CO to
increase OBF. To emphasize this, we present and discuss our
data related to the different organs.
Brain Blood Flow
A mismatch between brain blood flow (BBF) and cerebral
metabolic rate of oxygen during hypothermia is a much-
discussed topic (2, 26–29). Other studies state that, while
the cerebral metabolic rate of oxygen is normalized, BBF
remains reduced after rewarming. This indicates the existence
of maintained dysfunctional cerebral autoregulation (26, 30, 31).
Evidence of faulty cerebral autoregulation after rewarming is
reported and supports the presence of a concomitant change in
cerebral vascular function and hemodynamics (32–35). Under
non-pathological, normothermic conditions, neither SNP nor
LS will affect BBF (18, 36). In the present experiment, a 42%
reduction in CO corresponds to a 75% reduction of BBF in the
control group after rewarming. For comparison, studies during
normothermic conditions on healthy humans report that a 30%
reduction in COwould reduce BBF by only 10% (37). If we return
to the present experiment, different from the non-treated control
group, both SNP and LS elevated BBF similarly, 75 vs. 81%.
However, at the same time, SNP managed to elevated CO by only
14%, compared to 30% with LS. Thus, we interpret our findings
to disclose alterations of cerebral autoregulation after rewarming,
possibly due to elevated cerebral vascular resistance (32, 33). To
speculate, we suggest that differences in the effects of SNP and LS
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TABLE 2 | Hemoglobin (Hb), hematocrit, oxygen saturation (SaO2 ), oxygen saturation (pO2), arterial oxygen content (CaO2), venous oxygen content (CvO2), oxygen
delivery, (DO2); oxygen consumption, (VO2), at baseline (37
◦CBL ), during and after rewarming (30
◦CRW, and 37
◦CRW) from hypothermia in untreated and treated rats with
levosimendan or nitroprusside (each group n = 7).
Parameter Group 37◦CBL 30
◦CRW 37
◦CRW
Hb (g/dL) Control 12.56 ± 0.96 14.69 ± 0.25¤ 13.27 ± 0.84¤
Levosimendan 12.86 ± 1.18 14.29 ± 0.36¤ 13.01 ± 0.88¤
Nitroprusside 12.13 ± 0.71 14.04 ± 0.32¤ 12.77 ± 0.62¤
Hct (%) Control 38.63 ± 2.93 45.04 ± 0.74¤ 40.80 ± 2.55¤
Levosimendan 39.59 ± 3.53 43.80 ± 1.10¤ 39.99 ± 2.73¤
Nitroprusside 37.37 ± 2.12 43.13 ± 0.97¤ 39.29 ± 1.85¤
SaO2 (%) Control 86.29 ± 8.93 95.10 ± 0.77
¤ 91.80 ± 4.17¤
Levosimendan 88.46 ± 3.46 91.66 ± 2.53 92.13 ± 3.71
Nitroprusside 91.67 ± 2.98 94.76 ± 0.55 91.17 ± 4.28
pO2 (kPa) Control 9.77 ± 2.39 17.38 ± 1.41 12.22 ± 2.54
¤
Levosimendan 9.55 ± 1.01 15.28 ± 2.38 11.12 ± 1.87¤
Nitroprusside 12.16 ± 0.70 17.61 ± 0.85 12.31 ± 0.73¤
CaO2 (mg/dL) Control 14.71 ± 1.61 18.98 ± 0.39 16.58 ± 0.74
Levosimendan 15.49 ± 1.89 17.92 ± 0.79 16.32 ± 1.35
Nitroprusside 15.16 ± 0.70 18.25 ± 0.48 15.88 ± 1.03
DO2 (mg/min) Control 1,180 ± 142 766 ± 54
¤ 784.5 ± 89¤
Levosimendan 1,281 ± 117 935 ± 51¤* 1083 ± 81¤*
Nitroprusside 1,235 ± 103 820 ± 68¤ 866 ± 111¤
†
VO2 (mg/min) Control – – 465 ± 40
Levosimendan – – 586 ± 109*
Nitroprusside – – 521 ± 110
†
pH Control 7.35 ± 0.03 7.22 ± 0.03¤ 7.30 ± 0.04¤
Levosimendan 7.35 ± 0.04 7.22 ± 0.01¤ 7.33 ± 0.03¤
Nitroprusside 7.38 ± 0.02 7.20 ± 0.02¤ 7.28 ± 0.03¤
pCO2 (kPa) Control 5.01 ± 0.88 5.01 ± 0.42 4.11 ± 0.56
¤
Levosimendan 5.07 ± 0.26 5.50 ± 0.22 4.31 ± 0.38¤
Nitroprusside 4.52 ± 0.49 5.50 ± 0.17¤ 4.63 ± 0.34
Lactate (mmol/L) Control 0.90 ± 0.51 2.97 ± 0.23¤ 3.64 ± 0.84¤
Levosimendan 0.87 ± 0.51 3.01 ± 0.41¤ 3.26 ± 0.67¤
Nitroprusside 0.63 ± 0.19 3.93 ± 0.31¤
†
* 4.10 ± 0.52¤
BE (mmol) Control −4.60 ± 2.31 −11.80 ± 0.57¤ −10.16 ± 1.96¤
Levosimendan −3.94 ± 2.22 −10.23 ± 0.68¤ −8.41 ± 1.12¤
Nitroprusside −4.93 ± 1.45 −11.11 ± 0.67¤ −9.57 ± 1.07¤
HCO−3 (mmol/L) Control 20.44 ± 1.52 15.00 ± 0.58
¤ 16.54 ± 1.46¤
Levosimendan 21.02 ± 1.87 15.82 ± 0.46¤ 17.80 ± 0.90¤
Nitroprusside 20.53 ± 1.01 15.25 ± 0.53¤ 16.72 ± 0.84¤
Values are mean ± SD.
*P < 0.05 vs. control group at corresponding temperatures.
†
P < 0.05 vs. levosimendan group at corresponding temperatures.
¤P < 0.05 vs. 37◦CBL within-group (Holm–Sidak method).
to elevate BBF over those to increase CO are due to increased
cerebral vascular resistance. This increased vascular resistance
appears not to be expedient, and the vasodilator properties of
SNP and LS are the primary driving forces to improved BBF in
this study.
Myocardial Blood Flow
Aortic pressure and coronary resistance strongly regulate
myocardial blood flow (MBF) by myocardial metabolic
demand (38). While MBF is depressed after hypothermia,
the autoregulatory properties of the coronaries appear to be
unaltered. In this study, only the vasodilatory effects of SNP
caused the elevation of MBF. This is in concordance with
findings reported during normothermic conditions (18, 39).
Investigators have demonstrated a reduced MBF during
hypothermia with spontaneous circulation (2, 40–43). Further,
Berne revealed that the coronary regulation of flow is changed
in hypothermia. He argued that the coronary vessels are
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FIGURE 2 | Heart rate (HR), mean arterial pressure (MAP), stroke volume (SV), cardiac output (CO), cardiac index (CI), and systemic vascular resistance (SVR) at
baseline, during and after rewarming from hypothermia in untreated and treated rats with levosimendan or nitroprusside (each group n = 7). Values are mean ± SD. *P




P < 0.05 vs. levosimendan group at corresponding temperatures; ¤P < 0.05 vs. 37◦CBL within-group
(Holm–Sidak method).
relatively vasodilated during hypothermia, as the relative
reduction in MBF is lower than the change in aortic
perfusion pressure (41, 44). He stated that the effects of
hypothermia on coronary smooth muscle are relaxation and
that this is the main explanation for vasodilation, which
causes a high ratio between MBF and myocardial oxygen
consumption (41, 44).
In concordance with previous studies, the present study
also shows a reduced MBF during and after rewarming (2, 40–
43). Previously, we reported that the coronary vasculature
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has reduced sensitivity to endothelium-dependent and
independent vasodilation but normalized after rewarming
(45). This might indicate functioning vascular regulation after
rewarming. Although this study made no attempts to investigate
endothelium-dependent vasodilation in this study, we show that
SNP-induced endothelium-independent vasodilation resulted in
elevated MBF after rewarming from hypothermia.
Myocardial Function
A study from our group demonstrated LS to improve cardiac
contractility and CO after rewarming from hypothermia (10)
after using the present intact animal model. In the present
study, LS improved cardiac function without elevating MBF,
as demonstrated using the same model and dosage of LS.
Elevated cardiac contractility should elevate myocardial oxygen
consumption (46). Our findings might indicate that MBF
matches cardiac metabolic demands and that regulation of MBF
is preserved after rewarming. A similar conclusion was made
in earlier studies (25, 47). Lastly, in another study, LS did not
increase plasma cardiac troponin I, compared to non-treated
animals during rewarming. As the release of cardiac troponin is
a marker of myocardial damage, we understand this to indicate
the absence of further damaging factors such as hypoxia or
apoptosis (10).
Renal and Stomach Blood Flow
Previous studies have reported depressed renal blood flow (RBF)
following rewarming (2, 48). As both LS and SNP failed to
elevate RBF in response to elevated CO, the depressed flow
likely stems from other mechanisms than low CO. Hypothermia
and rewarming is associated with activation of the renin–
aldosterone–angiotensin system (RAAS) in both humans and
rats (49, 50). Broome et al. demonstrated that SNP did not
affect RBF during targeted vasoconstriction with angiotensin II
infusion (19). They interpreted that the vasoconstrictive effects
of angiotensin II supersede the vasodilatory effects of SNP
in the kidney. In the presented study, SNP failed to elevate
RBF. As in the experiment with Broome et al., the elevation
of the renin–aldosterone–angiotensin system might explain our
findings (49, 50).
In contrast to the RBF, Broome et al. found SNP to have
a vasodilating effect on stomach blood flow (SBF) during
angiotensin II-induced vasoconstriction (19). In the presented
study, SNP also elevated SBF. To speculate, our findings might
indicate that activation of the renin–aldosterone–angiotensin
system hormones as possible mediators of poor RBF and SBF.
Our results and reports from other investigators may support
these ideas, as they show that SNP only affects SBF and not
RBF, as well as increased renin–aldosterone–angiotensin during
hypothermia (49, 50). Further, studies from an identical model,
as presented, show renal tubular necrosis after rewarming (51).
Severe tubular necrosis is associated with renal vasoconstriction
and reduced RBF and explains why SNP and LS failed to
elevate RBF.
Clinical Significance
The physiological message this study brings to the
clinical table is to focus on the mismatch between organ
perfusion/microcirculation and global perfusion in the
hypothermia/rewarming setting. Routine bedside intensive
care lacks tools to assess organ perfusion and microcirculation
changes, continually and accurately, in response to treatment.
This highlights the need to be cautious in translating variables
related to global circulation into changes that are important
for organ blood flow and microcirculation, in this case, during
rewarming from hypothermia.
This experiment, describing both LS and SNP’s pharmacologic
effects to alleviate post-hypothermic circulatory dysfunction and
OBF in a rodent model, may encourage further research in large
animal models before clinical applications can be suggested.
Limitations
SNP is a known cyanide donor (52, 53). Enzymatic breakdown
of cyanide is done by the enzyme thiosulfate sulfurtransferase
(54). In critically ill patients, SNP-induced cyanide breakdown
is higher than production at SNP infusion rates below 2
µg/kg/min (55). However, studies have reported elevated cyanide
levels at lower infusion rates during hypothermia, possibly
due to low enzymatic activity. Therefore, investigators have
advocated for caution when using high doses or prolonged
use of SNP (56). Animals in this study received, on average,
2.9 µg/kg/min SNP and are, therefore, possible victims of
high cyanide levels, affecting the results. We do see possible
evidence of cyanide in the presented data. Both elevated
venous O2 and serum lactate are present in the SNP group,
although not significantly. Other investigators have toned down
the importance of cyanide poisoning by SNP, also during
hypothermia and cardiopulmonary bypass. Interestingly enough,
the SNP-treated animals, despite possible cyanide toxicity, had
improved hemodynamic and blood flow parameters compared to
the control group (52, 53).
CONCLUSIONS
From critical care reports, we know that efforts to elevate
OBF will improve end-organ function and patient survival. The
present findings indicate potential beneficial effects on organ
function by combining cardiac inotropic support and reducing
peripheral organ vascular resistance (15–17). In more detail,
our results demonstrate the beneficial effects of vasodilation
to increase CO and OBF, in general, and BBF, in particular.
While the inotropic effects of LS are shown to improve
CO, its relative weak additional vasodilator properties fail to
improve peripheral organ circulation.We, therefore, interpret the
vasodilator properties of LS and SNP to be the primary source to
increase organ blood flow, superior to the increase in CO.
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